Vivani Medical (VANI) Other Non-Current Liabilities (2021 - 2026)
Vivani Medical (VANI) posted quarterly Other Non-Current Liabilities of $16.5 million for Q1 2026, down 6.44% year-over-year from $17.6 million in Q1 2025, and down 3.33% quarter-over-quarter from $17.1 million in Q4 2025.
Vivani Medical (VANI) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Vivani Medical's Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $16.5 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 6.44% year-over-year to $16.5 million; the TTM figure through Mar 2026 stood at $16.5 million (down 6.44% YoY), while the FY2025 annual figure was $17.1 million, down 5.03% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $16.5 million, down from $17.1 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $20.1 million in Q2 2023, with the low at $42000.0 in Q3 2022.
- The 5-year median for Other Non-Current Liabilities is $17.6 million (2025), against an average of $14.7 million.
- The sharpest annual moves came in 2023 and 2025: Other Non-Current Liabilities surged 46754.76% in 2023, then dropped 7.58% in 2025.
- Vivani Medical's Other Non-Current Liabilities stood at $1.7 million in 2022, then surged by 1053.01% to $19.3 million in 2023, then declined by 6.98% to $18.0 million in 2024, then decreased by 5.03% to $17.1 million in 2025, then declined by 3.33% to $16.5 million in 2026.
- Business Quant data shows VANI's Other Non-Current Liabilities at $16.5 million in Q1 2026, $17.1 million in Q4 2025, and $16.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Vivani Medical | 120.18 Mn | 100.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.01 Mn |
| Mar 31, 2026 | 16.49 Mn |
| Dec 31, 2025 | 17.06 Mn |
| Sep 30, 2025 | 16.91 Mn |
| Jun 30, 2025 | 17.28 Mn |
| Mar 31, 2025 | 17.63 Mn |
| Dec 31, 2024 | 17.97 Mn |
| Sep 30, 2024 | 18.29 Mn |
| Jun 30, 2024 | 18.62 Mn |
| Mar 31, 2024 | 18.94 Mn |
| Dec 31, 2023 | 19.31 Mn |
| Sep 30, 2023 | 19.68 Mn |
| Jun 30, 2023 | 20.13 Mn |
| Mar 31, 2023 | 349,000.00 |
| Dec 31, 2022 | 1.68 Mn |
| Sep 30, 2022 | 42,000.00 |
| Dec 31, 2021 | 902,000.00 |